Aberrant protein activity rewires lymphoma cells to survive BTK inhibitors, offering target for treatment resistance
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The discovery points to a possible solution to the problem of BTK inhibitor treatment resistance.
Scientists at Weill Cornell Medicine have uncovered a mechanism through which some lymphoma cells resist treatment with BTK inhibitors. This protein, BRG1, helps these cells survive by suppressing a deadly process called ferroptosis. By blocking BRG1, researchers found that BTK inhibitors become more effective, potentially offering a new treatment option for patients with B-cell cancers.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
